Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHA:688566)
China · Delayed Price · Currency is CNY 25.79
-0.16 (-0.62%)
Sep 10, 2026, 1:14 PM CST
SHA:688566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,001 | 966.06 | 896.53 | 860.93 | 654.73 | 509.69 |
Other Revenue | 0.01 | 0.01 | - | - | - | - |
| 1,001 | 966.07 | 896.53 | 860.93 | 654.73 | 509.69 | |
Revenue Growth | 9.03% | 7.76% | 4.13% | 31.49% | 28.46% | -9.94% |
Cost of Revenue | 103.94 | 101.82 | 95.26 | 97.18 | 76.17 | 62.12 |
Gross Profit | 896.76 | 864.25 | 801.28 | 763.76 | 578.56 | 447.57 |
Selling, General & Admin | 600.44 | 563.08 | 458.54 | 459.86 | 361.56 | 304.65 |
Research & Development | 42.95 | 40.7 | 38.65 | 55.77 | 55.18 | 29.28 |
Other Operating Expenses | 15.72 | 13.51 | 9.77 | 10.47 | 9.24 | 9.1 |
Operating Expenses | 656.5 | 614.66 | 509.22 | 533.31 | 426.71 | 341.26 |
Operating Income | 240.26 | 249.58 | 292.06 | 230.44 | 151.85 | 106.32 |
Interest Expense | -0.27 | -0.27 | -0.13 | -0.11 | -0.38 | - |
Interest & Investment Income | 5.76 | 5.76 | 5.4 | 12.02 | 17.77 | 21.64 |
Other Non Operating Income (Expenses) | -47.86 | -0.11 | -0.11 | -0.14 | -0.07 | -0.11 |
EBT Excluding Unusual Items | 197.91 | 254.97 | 297.21 | 242.22 | 169.18 | 127.85 |
Gain (Loss) on Sale of Investments | -4.28 | -2.64 | -43.29 | -1.9 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.01 | - |
Asset Writedown | 0 | - | - | - | - | - |
Other Unusual Items | 48.81 | 48.81 | -0.56 | 7.16 | 5.37 | 4.71 |
Pretax Income | 242.44 | 301.13 | 253.36 | 247.48 | 174.53 | 132.56 |
Income Tax Expense | 33.9 | 40.14 | 34.39 | 28.71 | 20.27 | 18.22 |
Earnings From Continuing Operations | 208.53 | 261 | 218.98 | 218.77 | 154.26 | 114.35 |
Minority Interest in Earnings | 3 | 0.61 | 0.35 | 0.32 | 0.4 | 0.55 |
Net Income | 211.53 | 261.61 | 219.33 | 219.09 | 154.67 | 114.9 |
Net Income to Common | 211.53 | 261.61 | 219.33 | 219.09 | 154.67 | 114.9 |
Net Income Growth | -14.24% | 19.28% | 0.11% | 41.65% | 34.61% | -11.42% |
Shares Outstanding (Basic) | 199 | 200 | 194 | 187 | 186 | 188 |
Shares Outstanding (Diluted) | 199 | 200 | 194 | 187 | 186 | 188 |
Shares Change | -0.20% | 2.89% | 3.65% | 0.49% | -1.07% | 11.81% |
EPS (Basic) | 1.06 | 1.31 | 1.13 | 1.17 | 0.83 | 0.61 |
EPS (Diluted) | 1.06 | 1.31 | 1.13 | 1.17 | 0.83 | 0.61 |
EPS Growth | -14.06% | 15.93% | -3.42% | 40.96% | 36.07% | -20.78% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 137.09 | 133.71 | 40.76 | -197.87 | -141.98 | 66.77 |
Free Cash Flow Per Share | 0.69 | 0.67 | 0.21 | -1.06 | -0.76 | 0.35 |
Dividend Per Share | 0.520 | 0.520 | 0.780 | - | 0.480 | 0.480 |
Dividend Growth | 0% | -33.33% | - | - | 0% | 0% |
Gross Margin | 89.61% | 89.46% | 89.38% | 88.71% | 88.37% | 87.81% |
Operating Margin | 24.01% | 25.84% | 32.58% | 26.77% | 23.19% | 20.86% |
Profit Margin | 21.14% | 27.08% | 24.46% | 25.45% | 23.62% | 22.54% |
Free Cash Flow Margin | 13.70% | 13.84% | 4.55% | -22.98% | -21.68% | 13.10% |
EBITDA | 262.26 | 267.29 | 302.75 | 241.65 | 164.6 | 119.3 |
EBITDA Margin | 26.21% | 27.67% | 33.77% | 28.07% | 25.14% | 23.41% |
D&A For EBITDA | 22 | 17.71 | 10.7 | 11.2 | 12.75 | 12.98 |
EBIT | 240.26 | 249.58 | 292.06 | 230.44 | 151.85 | 106.32 |
EBIT Margin | 24.01% | 25.84% | 32.58% | 26.77% | 23.19% | 20.86% |
Effective Tax Rate | 13.98% | 13.33% | 13.57% | 11.60% | 11.62% | 13.74% |
Revenue as Reported | 966.07 | 966.07 | 896.53 | 860.93 | 654.73 | 509.69 |
Advertising Expenses | - | 225.33 | 161.69 | - | 153.2 | 121.29 |